Topical Ibuprofen Avoids Oral Pain Medication Problems

Topical Ibuprofen Avoids Oral Pain Medication Problems



ViaDerm FMG tm, a patent-pending 'needle-free' delivery system, has been successful in pre-clinical trials for pain management, blood sugar control, hormonal response, and is now available for licensing.



(PRWEB) June 6, 2003



Health Science Solutions ['HSS']is an advanced health care products research and development company with a wide range of specialty formulations, many of which utilize the Company's flagship topical cream-based delivery system - ViaDerm FMG tm.



ViaDerm FMG is a new, proprietary, alcohol-free drug delivery platform that enables rapid and efficient absorption of active agents through the skin and other membranes. ViaDerm FMG emulsions are permeation enhancers that temporarily change the dynamics of the skin or other membranes so that active molecules can be rapidly absorbed through the skin or other membranes and into the body.



HSS, a wholly owned subsidiary of All Natural FMG, Inc. launched its first commercial pain relief product, IbuCream tm, in March, 2003. IbuCream tm avoids the gastro-intestinal problems associated with oral pain medications.



Developed over 8 years ago and supported with pre-clinical feedback by over 4,000 patients, IbuCream tm is an emulsion containing 10 % ibuprofen and 1% lidocaine. Apparent benefits are the by-passing of the stomach, small intestines and liver as well as using less than the oral dose of 200 mg ibuprofen when IbuCream tm is applied directly to the site of pain. General patient feedback points to rapid onset of pain relief that can last up to 4 hours or longer.



IbuCream tm is delivered through the skin via a patent pending emulsion, ViaDerm FMG: Serial # 10/412,626 – “Alcohol-free transdermal analgesic composition and process for manufacture and use thereof.” IbuCream tm is available by prescription only at Post Haste Pharmacy in Hollywood.



All Natural FMG, Inc. also owns patent-pending Serial # 10/412,637 – “Alcohol-free transdermal insulin composition and processes for manufacture and use thereof.” Both patents are scheduled to be granted in Spring of 2005.



All Natural FMG, Inc. is negotiating with a South Florida University to conduct clinical studies re safety and effectiveness of IbuCream tm, and it seeks investors who want to participate in furthering the applications of ViaDerm FMG with RX-to-OTC drugs.



###